Reports Q4 revenue $32.5M, consensus $31.04M. Cash, cash equivalents, and short-term investments at December 31, 2022 was $122.0M compared to $102.4M at December 31, 2021. "Xeris had another record-breaking quarter to finish 2022 achieving net product revenue growth of 52% compared to last year and delivering 38% full-year net product revenue growth compared to 2021 on a pro forma basis," said Paul Edick, Chairman and CEO of Xeris Biopharma. "We enter 2023 well positioned to capitalize on that momentum with the continued growth of our commercial products, additional revenue from existing and potentially new partnerships and collaborations, advancement of our levothyroxine clinical program, and the continuing disciplined management of our cash. These key factors give us confidence that we are on track to achieve cash flow breakeven by year-end and position us to deliver continued growth and become a self-sustaining enterprise that does not require us to raise new capital to fund operations."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on XERS:
